Arrowhead Pharmaceuticals Valuation
| HDP1 Stock | EUR 15.94 0.06 0.38% |
At this time, the firm appears to be overvalued. Arrowhead Pharmaceuticals shows a prevailing Real Value of €15.23 per share. The current price of the firm is €15.94. Our model approximates the value of Arrowhead Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.4, profit margin of (0.56) %, and Current Valuation of 2.76 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Arrowhead Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Arrowhead Pharmaceuticals is based on 3 months time horizon. Increasing Arrowhead Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arrowhead stock is determined by what a typical buyer is willing to pay for full or partial control of Arrowhead Pharmaceuticals. Since Arrowhead Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arrowhead Stock. However, Arrowhead Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.94 | Real 15.23 | Hype 15.95 |
The real value of Arrowhead Stock, also known as its intrinsic value, is the underlying worth of Arrowhead Pharmaceuticals Company, which is reflected in its stock price. It is based on Arrowhead Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Arrowhead Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Arrowhead Pharmaceuticals helps investors to forecast how Arrowhead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arrowhead Pharmaceuticals more accurately as focusing exclusively on Arrowhead Pharmaceuticals' fundamentals will not take into account other important factors: Arrowhead Pharmaceuticals Total Value Analysis
Arrowhead Pharmaceuticals is currently projected to have takeover price of 2.76 B with market capitalization of 3.5 B, debt of 0, and cash on hands of 218.2 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Arrowhead Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.76 B | 3.5 B | 0 | 218.2 M |
Arrowhead Pharmaceuticals Investor Information
About 69.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 263.63. Arrowhead Pharmaceuticals recorded a loss per share of 1.29. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 17th of November 2011. Based on the key indicators related to Arrowhead Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Arrowhead Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Arrowhead Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arrowhead Pharmaceuticals has an asset utilization ratio of 35.15 percent. This implies that the Company is making €0.35 for each dollar of assets. An increasing asset utilization means that Arrowhead Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Arrowhead Pharmaceuticals Ownership Allocation
Arrowhead Pharmaceuticals holds a total of 108.31 Million outstanding shares. Over half of Arrowhead Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Arrowhead Pharmaceuticals. Please watch out for any change in the institutional holdings of Arrowhead Pharmaceuticals as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arrowhead Pharmaceuticals Profitability Analysis
The company reported the revenue of 243.23 M. Net Loss for the year was (176.06 M) with profit before overhead, payroll, taxes, and interest of 243.23 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Arrowhead Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Arrowhead Pharmaceuticals and how it compares across the competition.
About Arrowhead Pharmaceuticals Valuation
The stock valuation mechanism determines Arrowhead Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Arrowhead Pharmaceuticals. We calculate exposure to Arrowhead Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arrowhead Pharmaceuticals's related companies.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. ARROWHEAD PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 116 people.
8 Steps to conduct Arrowhead Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Arrowhead Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Arrowhead Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Arrowhead Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Arrowhead Pharmaceuticals' revenue streams: Identify Arrowhead Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Arrowhead Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Arrowhead Pharmaceuticals' growth potential: Evaluate Arrowhead Pharmaceuticals' management, business model, and growth potential.
- Determine Arrowhead Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Arrowhead Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |